Abrocitinib as a novel therapeutic approach for refractory prurigo nodularis: real-world evidence

Arch Dermatol Res. 2025 Mar 11;317(1):543. doi: 10.1007/s00403-025-04071-8.

Authors

Abdullah Demirbas¹, Esin Diremsizoglu², Gizem Cınar¹, Cigdem Vural³

Affiliations

¹ Department of Dermatology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye.
² Department of Dermatology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye. mdesinarslan@gmail.com.
³ Department of Pathology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye.

PMID: 40064674
DOI: 10.1007/s00403-025-04071-8

No abstract available

Keywords: Abrocitinib; Janus kinase inhibitors; Prurigo nodularis; Pruritus; Treatment outcome.

Publication types

Letter